Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00532909 | Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | PHASE1 | COMPLETED | 13 | — | — | Jul 1, 2006 | May 1, 2010 | Jul 16, 2012 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Vandetanib | DRUG | 100mg or 300mg By mouth every day continuous |
| Capecitabine | DRUG | Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14. |
| Oxaliplatin | DRUG | dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1. |
| Bevacizumab | DRUG | Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle) |
Inclusion Criteria: * Provision of signed informed consent. * Female and or male age 18 years and over. * Negative pregnancy test for women of childbearing potential. * Histologically or cytologically confirmed adenocarcinoma of the colon or rectum. * Patients with a history of colorectal adenocarc...